Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy

Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy

Aim. To assess the efficacy and safety of using the drug Extimia BIOCAD (international nonproprietary name INN: empegfilgrastim) in order to reduce the frequency and duration of neutropenia, the frequency of febrile neutropenia (FN) and infections manifested by FN in patients with lymphoproliferati...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ekaterina S. Nesterova, Tatyana Yu. Klitochenko, Natalya N. Glonina, Natalya V. Fadeeva, Tatyana A. Sannikova, Irina S. Lyalina, Tatyana V. Shelekhova, Dmitrij G. Sherstnev, Sergey V. Voloshin, Vladislav O. Sarzhevskii, Alina A. Hofman, Damir G. Ichshanov, Irina V. Poddubnaya
Format: article
Langue:RU
Publié: IP Habib O.N. 2021
Sujets:
non-hodgkin’s lymphoma
empegfilgrastim
pegylated colony-stimulating factor
clinical practice
prevention of neutropenia
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/f8ac47889d5d41f7a8c9e2650cc5399d
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/f8ac47889d5d41f7a8c9e2650cc5399d

Documents similaires